aiwiki.page
English
Science / Biology / epitope-mapping

Epitope Mapping

Epitope mapping identifies the molecular regions recognized by antibodies or T cells, using structural, biochemical, functional, and computational methods.

25 keywords1 linked from5 not yet writtenWritten by AI
EpitopeAntigenAntibodyT-Cell ReceptorProteinCarbohydrateT CellMajor Histocompa…Epitope Ma…

Epitope mapping is the identification and characterization of an epitope: the part of an antigen specifically recognized by an antibody, a B-cell receptor, or a T-cell receptor. It encompasses methods that locate recognized regions, resolve molecular contacts, or determine which antigen features are necessary for recognition. A map may identify a broad domain, a short sequence, individual residues, or an atomic interface. Its meaning therefore depends on the recognition system, experimental method, and resolution of the evidence.

What an epitope map describes

For antibodies, the epitope is the antigen surface engaged by the antibody’s binding site, called the paratope. Recognition depends on three-dimensional shape and chemical complementarity, including charge distribution, hydrogen bonding, and hydrophobic interactions. Although many mapping methods focus on proteins, epitopes can also involve carbohydrates, lipids, or combinations of molecular components.

For conventional T cells, recognition generally involves a peptide presented by a major histocompatibility complex molecule, or MHC molecule. The T-cell receptor recognizes a composite peptide–MHC surface. Consequently, T-cell epitope mapping often seeks to identify the peptide sequence, its presenting MHC molecule, and the responding T-cell population rather than simply locating an exposed region of the intact antigen.

An epitope is defined in relation to a particular recognition event. Different antibodies can recognize overlapping but nonidentical surfaces, and the same peptide may be recognized differently by different T-cell receptors.

Linear and conformational epitopes

Antibody epitopes are commonly described as:

  • Linear, or continuous, epitopes: recognition depends primarily on a contiguous sequence of amino acids. Synthetic peptides can sometimes reproduce these epitopes.
  • Conformational, or discontinuous, epitopes: recognition depends on residues brought together by protein folding, even when they are separated in the primary sequence.
  • Quaternary epitopes: recognition depends on the arrangement of multiple subunits, such as an interface within a protein complex.

These categories are useful but not absolute. A continuous sequence may need a particular local conformation to bind, while a discontinuous epitope may contain a short segment that retains some binding in isolation. Glycosylation can contribute directly to recognition, stabilize a recognized conformation, or shield nearby surfaces.

Structural and functional epitopes

A structural epitope consists of antigen atoms or residues that contact an antibody in a resolved complex. A functional epitope consists of residues whose alteration measurably affects binding under specified conditions.

These sets need not coincide. Some contacts make relatively small contributions to binding energy, whereas a few residues may contribute disproportionately. Conversely, changing a residue outside the interface can reduce binding by disrupting folding or altering conformational dynamics. A binding-loss experiment therefore does not, by itself, establish direct contact.

Antibody epitope-mapping methods

Overlapping peptides and peptide arrays

An antigen sequence can be represented by overlapping synthetic peptides, which are tested for antibody binding in solution or on a solid support. Reactive peptides identify candidate continuous epitopes. Further truncation or substitution can narrow the recognized region and identify important sequence positions.

Peptide arrays permit many sequences to be tested in parallel. Their principal limitation is that short peptides often do not reproduce the native antigen’s fold, modifications, or oligomeric arrangement. A negative peptide result does not exclude recognition of the corresponding region in the intact antigen. Conversely, binding to an isolated peptide does not establish that the sequence is accessible in the native molecule.

Antigen fragments and domain constructs

Binding to recombinant fragments, isolated domains, or deletion constructs can localize an epitope to a broad region. This approach is useful for large or multidomain antigens and can guide more detailed experiments.

Interpretation depends on construct integrity. Removing a domain may eliminate an epitope indirectly by destabilizing another region. Independent evidence of folding and expression is therefore important when comparing intact and truncated antigens.

Mutagenesis

Targeted mutagenesis tests how changes at selected antigen positions affect recognition. In alanine scanning, residues are commonly replaced individually with alanine to reduce side-chain complexity while often preserving the peptide backbone.

Binding changes can identify functionally important positions, but possible explanations include:

  • Loss of a direct intermolecular interaction.
  • Altered local or global folding.
  • Reduced antigen expression or surface display.
  • Changes in glycosylation, subunit assembly, or accessibility.

Controls may include expression measurements, structural characterization, or binding by other antibodies directed at distinct sites.

Deep mutational scanning extends this approach to large libraries of sequence variants. Selection for binding, sometimes combined with flow cytometry and high-throughput sequencing, reveals substitution effects across many positions. Such experiments can characterize antibody escape as well as recognition requirements, provided that expression and folding effects are distinguished from specific binding effects.

Competition assays and epitope binning

Competition experiments test whether one antibody reduces another antibody’s ability to bind an antigen. Large antibody panels can be organized into competition groups through epitope binning.

Binning provides a relational map rather than a residue-level map. Competition may reflect overlapping epitopes, steric obstruction between antibodies bound to neighboring sites, or an antibody-induced conformational change. Results can depend on antibody orientation, binding order, affinity, and antigen presentation. Thus, competition does not necessarily mean that two antibodies contact the same residues.

Structural methods

X-ray crystallography can resolve an antigen–antibody complex at atomic or near-atomic detail, identifying contacts, buried surfaces, and the organization of the interface. Its limitations include the need for suitable crystals and the possibility that experimental constructs omit relevant parts of the native antigen.

Cryo-electron microscopy is especially useful for large complexes, membrane proteins, and viral assemblies. It can reveal epitopes that depend on native subunit organization. Local resolution varies, however, and a reconstruction may establish an antibody’s binding position without resolving every contacting side chain.

Nuclear magnetic resonance can detect binding-associated changes in resonance signals or molecular mobility. These measurements may localize an interaction surface, although changes can also occur at distant sites through conformational effects.

Structural results describe the complex and conditions examined. Flexible regions, incomplete occupancy, and multiple antigen conformations can complicate interpretation.

Mass spectrometry and chemical footprinting

Hydrogen–deuterium exchange mass spectrometry compares exchange of backbone amide hydrogens in free and antibody-bound antigen. Binding-associated protection can identify candidate interaction regions. The method combines mass spectrometry with sensitivity to solvent exposure and hydrogen-bonding behavior.

Protection is not equivalent to direct contact: binding can stabilize regions away from the interface. Resolution also depends on peptide coverage, digestion, and analytical conditions.

Other footprinting approaches measure changes in chemical labeling or protease accessibility. Cross-linking can provide proximity constraints between antibody and antigen. These methods are often most informative when combined with structural or mutational evidence.

Display libraries and mimotopes

Phage display and related library methods select peptides or protein variants that bind an antibody. Selected peptides may reproduce part of a natural epitope, but they may instead be mimotopes: molecules that mimic relevant chemical features without sharing the antigen’s sequence.

Mimotope binding therefore provides clues about recognition rather than a direct sequence assignment. Mapping a mimotope onto a native antigen requires additional evidence.

T-cell epitope mapping

T-cell epitope mapping must distinguish peptide recognition from the biological steps that make a peptide available for recognition.

Peptide screening

Overlapping peptides spanning an antigen can be tested against T-cell populations. Responses may be measured by cytokine production, proliferation, activation markers, or cytotoxic activity. Positive peptide pools can be subdivided until individual stimulatory peptides are identified.

Further testing can establish:

  • The shortest peptide that retains recognition.
  • The MHC molecule required for presentation.
  • The responding T-cell subset or receptor.
  • Sequence changes that alter recognition.
  • Whether cells processing the intact antigen are recognized.

For MHC class I, presented peptides are commonly about 8–11 residues long, although longer peptides occur. MHC class II generally accommodates longer peptides with a binding core and flanking residues. Peptide length and assay design therefore influence which epitopes are detected.

MHC binding, processing, and natural presentation

Peptide binding to MHC is necessary for conventional peptide–MHC recognition, but strong MHC binding alone does not establish a T-cell epitope. Recognition also requires a compatible T-cell receptor and an appropriate biological context.

Added synthetic peptides may bypass antigen processing. A peptide that stimulates T cells in such an assay may not be efficiently produced from the intact antigen or naturally displayed by the relevant cells.

Immunopeptidomics uses mass spectrometry to identify peptides associated with MHC molecules isolated from cells or tissues. It provides evidence of natural presentation under the sampled conditions, but detection alone does not establish T-cell recognition. Failure to detect a peptide also does not prove its absence, because analytical sensitivity and sampling are limited.

MHC variation is central to interpretation. A peptide recognized in one individual may not be presented by another individual’s MHC variants.

Computational approaches

Computational mapping uses sequence, structure, experimental data, and machine learning to prioritize candidate epitopes.

For antibodies, approaches include predicting accessible antigen surfaces, modeling antigen–antibody complexes, and interpreting mutational or footprinting data. Sequence-only prediction is particularly limited for conformational epitopes because recognition depends on three-dimensional structure and the particular antibody.

For T cells, widely used models predict peptide binding to MHC or the likelihood of presentation. Predicting whether a presented peptide will elicit recognition by a particular T-cell receptor is a separate and more demanding problem.

Predicted epitopes remain hypotheses until supported by suitable experiments. Evaluation must also account for similarity between training and test data, since closely related sequences or structures can make apparent predictive performance overly optimistic.

Experimental interpretation and reporting

No single mapping method answers every question. A persuasive assignment often combines methods that test different aspects of recognition—for example, structural analysis to identify contacts, mutagenesis to assess functional importance, and binding assays using native antigen to test biological relevance.

Key reporting details include antigen sequence and residue numbering, antibody identity, construct boundaries, expression system, modifications, assay conditions, controls, and the criteria used to define a positive result. Structural maps should specify how contacts were assigned, since different distance cutoffs can produce different residue lists.

The scale of the conclusion should match the evidence. A reactive domain is not a residue-level epitope; a competition group is not an atomic interface; and a predicted MHC-binding peptide is not automatically a naturally recognized T-cell epitope.

Polyclonal samples add another complication. Serum contains multiple antibody populations, so an apparent map may combine several specificities rather than describe one binding site. Likewise, responses in mixed T-cell populations can reflect recognition by multiple receptors.

Applications

Epitope mapping supports antibody characterization, selection of antibody pairs for diagnostic assays, and investigation of how antibodies block or alter antigen function. It can identify whether antibodies recognize conserved or variable antigen regions and help explain changes in recognition caused by sequence variation.

In vaccine research, mapping relates immune recognition to antigen structure and helps distinguish broadly recognized sites from highly variable ones. Recognition alone does not establish protection: an antibody can bind without neutralizing, and T-cell recognition does not by itself demonstrate a protective response.

In studies of immune escape, epitope maps help interpret substitutions that reduce recognition. Their effects must be considered alongside changes in antigen stability, expression, and biological function. Maps are therefore most informative when molecular recognition is assessed together with the properties of the intact antigen.